title: [Novel therapeutics for COPD].
abstract: Chronic obstructive pulmonary disease (COPD) is a progressing lung disorder mainly caused by cigarette smoking. The central pathogeneses are inflammation, oxidative stress, apoptosis and excessive proteases which lead to matrix degradation and loss of lung cells. The inflammation is somehow perpetuated even after quit smoking and is generally refractory to glucocorticoid therapy. It is thus hoped to develop novel anti-inflammatory agents for prevention of disease progression. As molecular mechanisms of COPD are gradually clarified, numerous numbers of molecular targeted agents have been developed for therapeutics. In this section, novel agents for COPD targeted at signal transduction molecules, cytokines, chemokines and those receptors, adhesion molecules, oxidative stress and proteases are discussed.
authors.affiliation: Department of Respiratory Medicine, Kyoto University Hospital.
authors.forename: Yuma
authors.initials: Y
authors.lastname: Hoshino
authors.forename: Shigeo
authors.initials: S
authors.lastname: Muro
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mishima
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001993:Bronchodilator Agents; D011480:Protease Inhibitors